• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ACS Sens . CRISPR Systems for COVID-19 Diagnosis

tetano

Editor, Senior Moderator
ACS Sens


. 2021 Jan 27.
doi: 10.1021/acssensors.0c02312. Online ahead of print.
CRISPR Systems for COVID-19 Diagnosis


Hossein Rahimi[SUP] 1 2 [/SUP], Marziyeh Salehiabar[SUP] 3 4 [/SUP], Murat Barsbay[SUP] 5 [/SUP], Mohammadreza Ghaffarlou[SUP] 5 [/SUP], Taras Kavetskyy[SUP] 4 6 7 [/SUP], Ali Sharafi[SUP] 2 [/SUP], Soodabeh Davaran[SUP] 3 4 [/SUP], Subhash C Chauhan[SUP] 8 9 [/SUP], Hossein Danafar[SUP] 2 4 [/SUP], Saeed Kaboli[SUP] 1 [/SUP], Hamed Nosrati[SUP] 2 4 [/SUP], Murali M Yallapu[SUP] 8 9 [/SUP], Jo?o Conde[SUP] 10 11 [/SUP]



Affiliations

Abstract

The emergence of the new coronavirus 2019 (COVID-19) was first seen in December 2019, which has spread rapidly and become a global pandemic. The number of cases of COVID-19 and its associated mortality have raised serious concerns worldwide. Early diagnosis of viral infection undoubtedly allows rapid intervention, disease management, and substantial control of the rapid spread of the disease. Currently, the standard approach for COVID-19 diagnosis globally is the RT-qPCR test; however, the limited access to kits and associated reagents, the need for specialized lab equipment, and the need for highly skilled personnel has led to a detection slowdown. Recently, the development of clustered regularly interspaced short palindromic repeats (CRISPR)-based diagnostic systems has reshaped molecular diagnosis. The benefits of the CRISPR system such as speed, precision, specificity, strength, efficiency, and versatility have inspired researchers to develop CRISPR-based diagnostic and therapeutic methods. With the global COVID-19 outbreak, different groups have begun to design and develop diagnostic and therapeutic programs based on the efficient CRISPR system. CRISPR-based COVID-19 diagnostic systems have advantages such as a high detection speed (i.e., 30 min from raw sample to reach a result), high sensitivity and precision, portability, and no need for specialized laboratory equipment. Here, we review contemporary studies on the detection of COVID-19 based on the CRISPR system.

Keywords: COVID-19; CRISPR; RT-qPCR; SARS-CoV-2; diagnosis.
 
Back
Top Bottom